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Abstract. 
 
Calcium homeostasis is a very exact homeostasis responding to a very small 
fluctuation in the extracellular calcium ion concentration. One of the keys to the 
regulation of this homeostasis is the calcium sensing receptor.  
The aim of this project was to sequence the untranslated region of the calcium 
sensing receptor gene, including exon 1A, exon 1B and the respective promoter 
regions, to see if there were DNA-variants or mutations which could be related to a 
specific clinical diagnosis, based on dysfunction in the calcium homeostasis. 
Several reports in which the authors in part has sequenced the untranslated 
regions, have purified and sequenced different mRNAs and related the sequence 
they found to either a specific diagnose or to the regulation of the gene. 
Furthermore, from previous studies I have purified DNA from 23 patients that have 
a diagnosis related to dysfunction in the calcium homeostasis. The DNA from these 
patients were sequence in the encoding exons 2-7and most of them without any 
mutation. In the light of this it would be interesting to analyze the untranslated 
regions of the calcium-sensing receptor gene from these patients to see if there 
could be associations with the diagnoses. 
To do this I have designed eight primers to amplify the DNA sequence of the 
untranslated region of the calcium sensing receptor by the polymerase chain 
reaction followed by direct sequence analyzing on an ABI 3100 Genetic Analyzer.  
In seven of the patients I found the respective genotypes: GGG, GAG and GG/AG 
in the untranslated exon 1B, 111 nucleotides upstream of the splice site. The 
conclusion according to the results of this project could be that the genotype 
GGG leads to familial hypocalciuric hypercalcemia (FHH), the genotype GAG 
leads to primary hyperparathyroidism (PHPT) and the heterozygous genotype G 
(G/A) G leads to the phenotypes of FHH, PHPT and autosomal dominant 
hypoparathyroidism (ADH). Further studies of the untranslated region of the 
calcium-sensing receptor has to be done to find an association between 
mutations and /or polymorphism to the diagnose. Even though, it is not possible to 
make any statements whether one of these genotypes is just polymorphisms or a 
disease-causing mutations until the frequency of these DNA variants has been 
determined in the background population. 
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Introduction 
 
1.1 Calcium homeostasis  
 
Calcium homeostasis is a very exact homeostasis responding to very small 
fluctuations in the extracellular calcium ion concentration (Ca2+0), the normal 
Ca2+0 in the body is maintained within a narrow range of 1,1-1,3 mM. This precise 
control is essential, because calcium plays a key role in many physiologic 
processes, including transmission of nerve impulses, blood clotting, contraction of 
skeletal, cardiac and smooth muscles. Furthermore, calcium is a key player in 
bone biology and in many hormonal regulations as well as different cellular 
functions, where the calcium ion is either a first and/or a second messenger. Ca2+0    
is a result of the balance between intestinal calcium absorption, renal calcium 
excretion and release from/uptake in the bone. The regulation of Ca2+0 is 
mediated via the calciotropic hormones, and the calcium sensing receptor 
(CASR) is the key receptor in the feedback regulation of the release of these 
hormones. The receptor is highly expressed in the kidney, the intestines and in bone 
as well as in the parathyroid glands where the synthesis of parathyroid hormone 
(PTH) is located, se figure 1. Parathyroid hormone is the main regulator of Ca2+0.
If the regulation of the Ca2+0 fails, many organ systems will be affected. Most 
importantly hypocalcemia will induce increased excitability of the nervous system 
with risk of tetany, which occurs when Ca2+0 falls to approximately about 0.40 mM. 
In the most severe form, it can cause seizures caused by the increasing excitability 
in the brain (Guyton 2000, Hall 2000). 
 
 
Ambye, Vejlefjord, Nov.2005 
Figure 1: The calcium homeostasis in humans. The key to this homeostasis is the expression of CASR 
in the chief cells in the parathyroid glands, in thyroid C-cells, kidney tubule cells, and at lower levels 
in bone and intestinal cells. The figure shows the regulation that occurs when the Ca2+0 decreases.  
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Because the calcium ion is ubiquitous and have many essential roles the 
Calcium homeostasis is a very exact regulated homeostasis; the key to this 
regulation is the expression of CASR in the chief cells in the parathyroid gland, 
where CASR serves as the primary physiological regulator of PTH secretion, in 
thyroid C-cells, kidney tubule cells, and at lower levels in bone and intestinal cells. 
The CASR in these organs recognize and respond to very small fluctuations in the 
Ca2+0, maintaining the normal Ca2+0  in the extracellular space within a narrow 
range of 1.1-1.3 mM. Even a small fluctuation of 1-2% will via the CASR regulate the 
synthesis and secretion of the calcium-regulating hormones: parathyroid hormone 
(PTH), calcitonin (CT) and 1.25 dihydroxyvitamin D3, also called the calciotropic 
hormones.  
CT is synthesized in the thyroid C-cells and acts in the bone. CT has a minor role as 
calcium-lowering hormone. The hormone acts within seconds or minutes to 
reestablish the Ca2+0 and there is a positive relationship between Ca2+0, and CT. 
When Ca2+0 increase, the CASR will increase synthesizes of CT and thereby 
inducing uptake of calcium in bone (Fudge, et al., 2004).  
The hormone 1. 25 dihydroxyvitamin D3 is the active form of vitamin D3 and PTH, 
which induces convertion of vitam D3 to 1.25 dihydroxy-vitamins D3, promotes this 
form.  Like PTH, this hormone is active in bone, kidney and in the intestines. The 
vitamin D metabolism will be affected after sustained change in the Ca2+0 level 
(Chen, 2004). 
PTH has the dominant role in the homeostasis as the calcium-elevating hormone 
and exerts its actions in bone, kidney and the intestines, see figure 1. There is a 
steep inverse sigmoid relationship between Ca2+0 and PTH. This means that if the 
extracellular concentration of calcium is high, the synthesis and secretion of PTH 
will be inhibited and vice versa (see figure 2). The calcium set-point is defined as 
the blood ionized calcium concentration where the PTH secretion is 50% of the 
maximal PTH secretion. This set-point is often used in the clinical evaluation of 
diseases. 
PTH is a peptide hormone, which is synthesized in and secreted from the 
parathyroid chief cells. PTH has both an indirect and a direct effect of maintaining 
the Ca2+0 by acting in target tissues, which is bone where calcium will be released, 
and the renal tubular, where the reabsorption of Ca2+ increases if the Ca2+0 is 
decreased and PTH thereby is high. An elevated PTH level will also increase the 
expression of CASR in the kidney as well as the 1, 25 dihydroxyvitamin D3 will 
(Abukawa et al., 2001). In contrast, Riccardi et al., (1996) have shown that 
treatment of rats with PTH decreases the CASR expression in proximal tubules. 
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Schwarz P et al., Ugeskrift for læger, 2005 
Figure 2: The inverse sigmoid relationship between blood ionized calcium and serum parathyroid 
hormone (PTH) in vivo. A) maximal PTH secretion, B) calcium set-point defined by E50, C) the 
physiological calcium set point defined as the individual basal calcium value D) the minimal PTH 
secretion.  
 
The indirect action of PTH is in the kidney, where elevated PTH levels will increase 
the convertion of 25 hydroxyvitamin D to 1.25 dihydroxyvitamin D3, which will 
increase the absorption of calcium from the intestines, bone and kidney. 
1.25 dihydroxyvitamin D3 has the additional effects in parathyroid cell where it 
inhibits the transcription of the PTH gene and reduces the cell proliferation (Brown  
et al., 1995). 
Recently Canaff et al. have found that the transcription of CASR increases after 
treatment with 1.25 dihydroxyvitamin D3 in thyroid, parathyroid and kidney cells in 
rat (Canaff et al.2002). In addition, they have identified a functional vitamin D 
response element upstream of the gene in each of the two promoters of the 
human CASR gene.  
 
1.2 Calcium sensing receptor, the protein and the function: 
 
In 1993 Brown et a., cloned the bovine parathyroid calcium sensing receptor 
(BoPCASR) from the mRNA of bovine parathyroid gland injected in Xenopus laevis 
oocytes, and thereby isolated the cDNA of CASR. In 1993, Martin Pollak cloned the 
mammalian CASR using the same technique. Pollak and Brown published in 1995 
the cloning and characterization of the BoPCASR and they found the topology of 
the receptor constructed from the cDNA. They found the receptor to have three 
major structural domains, see figure 3.  
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The first domain is a large amino-terminal extracellular domain (ECD) with 613 
amino acids, which includes the 19-signal sequence peptide, as well as multiple N-
glycosylated sites. The signal peptide predicts the translocation of the nascent 
polypeptide to the ER, where the glycosylation takes place. Mutation within this 
signal peptide will reduce the expression of the receptor at the cell membrane 
surface and reduce the intracellular pathway signal (Pidasheva, 2005). The second 
domain is the transmembrane domain (TMD), which contains seven membrane-
spanning helices of 250 residues, which characterizes the G protein-coupled 
receptor (GPCR) family. The third domain is the intracellular domain (ICD), which 
are the C-terminal containing 222 amino acids (Brown et al., 1995). The ICD has 
three phosphorylations sites for phosphokinase C and the intracellular loop 2 and 3 
have one each. Both the phosphorylations sites at the tail and loops are important 
for the intracellular pathway of the activation of CASR. 
 
Brown et al 1995. 
Figure 3: Schematic representation of the principal predicted topology of the extracellular calcium 
sensing receptor (CASR) cloned from human parathyroid glands. The extracellular domain (EDC) 
contains approximately 600 amino acids, the transmembrane domain (TMD) and the intracellular 
domain (ICD) each contains approximately 200 amino acids. Also illustrated are the 
phosphorkinase C (PKC) phosphorylations sites, the N-glycosylation sites and cysteine residues.  
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In human, the CASR is composed of 1078 amino acids (Garrett et al., 1995). The 
gene is located on chromosome 3q21-24 (Janicic et al., 1995), and the receptor is 
expressed in several different tissues at the surface of the cell. The mainly 
homeostasis effect are primarily in the thyroid C-cells, parathyroid glands, kidneys, 
bone and intestines. Studies reveal that members of the GPCR’s often form a 
dimer at the cell surface. This is also the case for the CASR residues at the cell 
surface where two monomers of CASR are linked covalently by disulfide bonds 
between the cysteine residues 129 and 131 in the functional CASR (Bai et al., 1998). 
The ECD of the GPCR form a Venus flytrap module that contain the ligand binding 
site, which is highly conserved both compared to other classes of GCPRs in 
humans as well as in other species. The CASR also forms a Venus flytrap module 
containing the Ca2+ binding site, amino acids (aa) S169, S170, S171 and S297 and 
has been found that mutations at these binding sites have been characterized by 
perturbations of the calcium homeostasis (Silve et al., 2005). 
The CASR is the first known receptor that permits an ion (Ca2+) to play a “hormone 
like” role as a first messenger, in addition to the well-known role as an intracellular 
second messenger (Brown et al., 1995). 
According the activation of the receptor’s intracellular pathway there are 
different opinions among the authors. Some authors suggest that the activation of 
the receptor occurs when Ca2+ bind to EDC and thereby create a configuration 
change of the TMD which leads to the activation of the intracellular pathway. 
Others suggest that Ca2+ binding leads to a configurative change in ECD, which 
again leads to an interaction between the EDC and the extracellular loops, and 
that, it is this interaction, which results in activation of the intracellular pathway. (Hu 
et al., 2002, reviewed by Chen et al., 2004). 
 
 
However, the intracellular pathway of the CASR will be activated when Ca2+, Mg2+, 
Gd3+, neomycin or other divalent cations bind to the receptor. As it is a GPCR it will 
mediate a response by binding two G-proteins, CASR bind Gq11, when the 
Gq11binds to CASR the alfa-subunit will dissociate and activate phospholipase C 
(PLC), PLC catalyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5 
triphosphate IP3 and 1,2 diacylglycerol (DAG). IP3 binds to calcium channels in the 
endoplasmic reticulum (ER), which opens and releases Ca2+ into the cytoplasm 
thereby increasing the intracellular Ca2+ (Ca i2+). The elevated Ca i2+ increases the 
Ca2+ influx by voltage gated calcium channels and Ca i2+ activate PKC that 
mediates the activation of mitogen-activated protein kinase (MAPK). The other G-
protein that binds to CASR is G i and through PTX-sensitive G i interrupts cAMP 
production (Kifor et al., 2001) (Hofer et al., 2005). However, the signalling 
mechanisms can vary depending on the cellular context. Some features of CASR-
mediated signal transduction pathways in human embryonic kidney 293 (HEK293) 
cells and parathyroid cells are shown in figure 4. The classical pathway of CASR is 
that the high concentration of Ca i2+ inhibits transcription of PTH gene and thereby 
decreasing the secretion of PTH. The result is an increase in renal Ca2+ excretion, 
and a decrease in intestinal Ca2+ absorption, which decreases the Cao2+. When 
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CASR are inactive, when no ligand binds, the specific aa-sites for phosphorylations 
will be phosphorylated and the association with the G alfa-subunit is inhibited.  
Ca2+ inhibits, together with vitamin D-complex, the transcription of PTH gene by 
binding to the promoter (Canaff et al., 2002).  
 
 
Hofer et al., 2005. 
Figure 4: The signal transduction mediated by the calcium-sensing receptor (CaR). When Ca02+ 
binds to the CaR a complex network of intracellular signal-transduction cascades are activated. 
Please refer to the text for further details.  
 
1.3 Calcium dependent diseases 
 
The discovery and cloning of the CASR have lead to the elucidation of the pivotal 
roles of the CASR in the systemic calcium homeostasis. The receptor has been 
found to be widely expressed in various tissues and likely serves important cellular 
functions beyond that of maintaining the systemic calcium homeostasis. The CASR 
takes part in the pathophysiology in many different diseases. Functional important 
mutations have been found to cause disorders in calcium homeostasis due both to 
the change in the set point for PTH secretion and the regulation of the renal 
calcium excretion. These mutations can either cause hypercalcemia when the 
mutation leads to inactivation of the receptor or hypocalcemia when the 
mutation leads to activation of the receptor. This type of mutation will make a shift 
in the set-point, se figure 5. Recent studies have revealed the presence of 
circulating autoimmune antibodies to the receptor that result in the same 
symptoms as mutations in CASR. Discovery of the receptor has open up for a 
variety of possibilities for instance development of specific drugs or new ways of 
medical treatment. (Tfelt-Hansen et al., 2003). 
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Tfelt-Hansen  et a.,l. 2005. 
Figur 5:  Presentation of the blood Ca2+ and serum PTH sigmoidal relation in normal state, in 
autosomal dominant hypoparathyroidism ADH (activating mutation) and familial hypocalciuric 
hypercalcemia FHH (inactivating mutation), set point is defined as the calcium concentration 
causing half-maximal inhibition of secretion. (Reviewed by Tfelt-Hansen et al., 2005).  
 
The diseases caused by disorders in the CASR can be divided further into 5 
categories:   
1. Diseases arise from alterations in the receptor functions, caused by 
inactivating or activating mutation in the receptor. (A) Familial 
hypocalciuric hypercalcemia (FHH) which is caused by a mutation in 
on allele of CASR gene, a heterozygote mutation that partially or 
completely inactivates CASR, an autosomal dominant disease 
(Pollak et al., 1993). (B) Neonatal severe primary hyperparathyroidism 
(NSPH) which occurs if the mutation is found in both alleles of CASR, a 
homozygote mutation, that normally are lethal (Pollak et al., 1993). 
(C) Autosomal dominant hypoparathyroidism (ADH) is due to a 
hypersensitive receptor for Ca02+, an activating mutation (Pollak et 
al., 1994). 
2. Diseases in which the CASR is the target for autoimmune antibodies (Li et al., 
1996). 
3. Diseases in which the CASR protein is without mutations but the amount of 
expressed receptors at the cell surface is reduced, as is the case of primary 
hyperparathyroidism (PHPT) and some times in secondary hyperparathyroidism 
(SPHPT). Mutations in the UTR exon 1A or B and/or mutations in their promoter 
might be involved in the pathogenesis. (Canaff et al., 2002). 
4. Diseases in which the function of the CASR gene’s are modified due to 
polymorphisms.  
5. Malignant diseases in which the CASR may be involved in the pathophysiology 
of hypercalcemia. 
 
 10
Mutations that cause all these diseases can be nonsense, missense, insertion, 
deletions or splice site mutations found throughout the CASR gene (Hendy et al., 
2000). A list of all mutations in CASR can be found at: 
http://www.casrdb.mcgill.ca/. 
 
1.4 Calcium sensing receptor gene structure 
 
The gene that encodes the CASR consists of six coding exons (exon 2-7)(see figure 
6).The first 242 nucleotides of exon 2 is a 5‘- untranslated region (UTR) followed by 
the translation start site and throughout exons 7 the CASR gene is translated 
(Chikatsu et al., 2000). The coding region of CASR consists of 3234 nucleotides and 
the protein consists of 1078 amino acids (aa). The last 230 nucleotides in exon 2 
and through out to the first 1836 nucleotides in exon 7 encode for the first 612 aa 
which constitute the ECD. All TMD’s are encoded by the nucleotides 1836 to 2586 
in exon 7. The remaining nucleotides are coding for the 863-1078 aa which 
constitute the ICD.  
 
 
Ambye, 2005. 
Figure 6: The structure of the CASR gene. The gene contains two UTR‘s exons 1 and half of the exon 
2 is as well UTR, the coding exons are half of exon 2 and trough out exon seven. 
 
As shown in figure 6 the CASR gene has two alternative first exons 1; 1A and1B, that 
are not translated. The two exons are transcribed and spliced together with exon 2 
independent of each other. The function of these two splice variants is not known 
in details. In 1995, Garrett et al., isolated cDNA with different 5’UTR from 
parathyroid adenomas and in 1996Pearce et al., reported that there was at least 
one 5’ untranslated exon in the CASR gene. Today we know that there is a 
promoter region for each exon 1 with each respective promoter regions P1 and 
P2. The transcriptional start site of the two exons have been mapped and 
characterized. The promoter P1 of the CASR gene has a CAAT-box -101 
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nucleotides and a TATA box  -26 nucleotides upstream of the transcriptional start 
site of exon 1A. Whereas the sequence upstream of exon 1B lacks the TATA- box 
but is a very GC-rich region and it is found that it contains two SP 1 sites in the P2 
region, one 11 base pair (bp) upstream and a second three bp downstream the 
transcriptions start site of exon 1B (Canaff et al., 2002). 
In addition Canaff et al. has identified a vitamin D response element (VDRE) in 
each of the two promoters and found that vitamin 1,25(OH)2D3 up-regulates 
CASR’s mRNA in human kidney and thyroid cell lines(Canaff et al., 2002). 
Moreover, they show that P2 has a higher expression level in kidney cells 
compared with the expression of P1 and that P2 represent elements important for 
tissue specific expression of the human CASR gene. Another known consensus 
sequence in the promoters is the element for binding of the transcription factor NF-
кB that is regulated by cytokines (Canaff et al., 2005). 
In 2000 Chikatsu et al., analyzed the different expression levels of the different 
mRNA’s in normal and parathyroid adenoma cells. The results indicate that 
expression of exon 1A is reduced in parathyroid adenomas, whereas the 
expression of exon 1B is not different between the two cell types, see figure 7. 
 
 
Ambye, 2005. 
Figur 7: The CASR gene’s promoter structure of exon 1A and 1B with the respective upregulating 
elements; vitamin D response element (VDRE) and transcription factor NF-кB. 
 
The fact that the CASR gene has two promoters and two different first exons makes 
it possible to create alternative splice mRNA variants. The reason why my interest 
was awakened is that I from previous studies have 23 patient’s DNA. These patients 
have a clinical diagnosis and I have sequenced the DNA for the common known 
exons 2-7 of the CASR. The clinical diagnosis is divided in eight patients with PHPT, 
seven with FHH, four with ADH, two with NSHPT and two who has a dysfunctional 
calcium homeostasis. The sequencing of the DNA for the common known exon:  2-
7 of CASR has only resulted in few DNA non-coding variants and three mutations in 
the coding region. There is a relationship between those findings in the way that a 
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family with the diagnosis ADH has a missense mutation in the cystein-rich area 
where the dimerization takes places which is known to be a "hot spot" for 
activation mutations. These results leave the rest of the patients (17) without DNA-
variants in the coding regions, but with a clear diagnosis. It will therefore be of 
much interest to see if mutations or DNA-variants in the 5’-UTR including the exon 
1A, exon 1B and their respective promoters and/or in any of the transcriptional 
elements could be associated with the diagnosis.  
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Experimental procedure. 
 
2.1  Collection of DNA:  
 
The collection of the DNA samples from the diagnosed patients has been a co-
operation between doctors on the different hospitals on Sjælland. The doctors 
have the contact to the patient in the connection of an endocrinology 
department where the patient is coming for treatment of their illness. Every patient 
has had a diagnosis or at least a supposition about what kind of diagnosis they 
can expect. The doctor then orders a blood test taken from the patient and 
together with a form, which describes either the diagnosis or the proposed 
diagnosis. We receive the blood and registration of the patient.  
 
2.2 Purification of DNA: 
 
When receiving the blood we isolated the DNA by using a DNA extraction kit for 
mammalian blood (Roche Applied Science Cat.no. 11667327001). 
The principle for this method is; to separate the white blood cells from the whole 
blood by lysis of the red blood cells, then lysing the white blood cells in a strong 
anionic detergent and then removes the proteins by dehydration and 
precipitation. Subsequently the purified DNA was recovered by ethanol 
precipitation and resuspending in 1 X TE-buffer (see appendix p. 32). The exact 
concentration and A260/ A280   ratio of the purified DNA is quantified using a 
Genequant II spectrophotometer (Pharmacia Biotech). 
 
2.3  Design of primer: 
 
To design the primer for the PCR amplification of the exon 1A and 1B, subsequently 
their promoter in CASR gene, I have used the OLIGO 6.0 software (Molecular 
Biology Insights, Cascade, CO, USA). This was done by copying the human 
sequence for chromosome 3q21-3q24: NT_005612 REGION: 28384824..28513339, 
then the ORIGIN (reference sequence) for CASR will show up and it is then possible 
to find the sequences for P1, P2, exons1A and exons 1B. The sequence that 
Chikatzu et al. published in 2000 and Canaff et al., 2002 (see figure 17 appendix p. 
33-34). Then paste this sequence into the OLIGO 6.0 software. I have chosen the 
sequence 75 bases upstream from the CAAT- box. In the program, I design how 
long the PCR product should be, and that is 350-500bp and how many bases I 
want the primer to be; I have defined the primers to be from 20-25bp. The software 
will then search for possible primer pair sequences in the specified sequence I 
have chosen.   
However, it is possible to define many different parameters in the program before 
the search is started e.g. elimination of ambiguous bases, duplex-/ hairpin-free 
primers or specific annealing temperature etc. After the search, the program listed 
all PCR-primer pairs that are possible in the sequence under the desired conditions.  
The content of the list for each primer-set is; the position of each of the forward/ 
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reverses primers in the sequence, the product length, %-GC content and the 
optimal annealing temperature. The result of my search was a list of 143 primer 
sets.  From that list, one first will find these primer-sets within a narrow annealing 
temperature that I chose to be 55-60 °C. Empirically it is not necessary to use 
exactly that temperature the program proposed to get a specific polymerase 
chain reaction (PCR) product. Now it is important to check if the primer it self, or 
the forward and reverse primers make any inter- or intra-molecular annealing due 
to duplex formation. After this thorough analyse each forward and reverse primer 
are blast against Ensemble’s gene database for Homo sapiens. 
http://www.ensembl.org/Homo_sapiens/geneview?   
The blast result brings the very important information about how many places this 
specific primer sequence is homologues with sequences in the human genome 
(hits), and where this homology is located in the genome. In addition, you get the 
information on how many of the bases of the primer that anneal and a picture of 
the primer in the sequence of interest. After a critical analysis, you choose those 
primers with 1 or 2 “hits” and the ones who cover the whole required sequence for 
your PCR amplification. Those primers I ordered at the company TAG-
Copenhagen that synthesis primers. 
 
2.4 Set-up and optimization of the PCR amplification: 
 
To amplify the specific sequence of exon 1A and 1B and the respective promoters 
P1 and P2 I have used the PCR technique (Kary Mullis, 1984). The principle of PCR is 
three steps: 1) denaturation of the DNA α-helix by heat higher then or equal to 94 
°C. 2) Hybridizing the designed primers to the complementary strand of the DNA, 
at temperature that is optimal for the specific primers. 3) Synthesis of the new DNA 
strand by heating the solution to 72 °C, the optimal temperature for the Taq DNA 
polymerase. I have used AmpliTaq Gold® with Geneamp®( (Applied biosystem. 
Pat.no 4311816).  
The DNA I use in the optimization of the first trials was partly DNA isolated from a 
blood donor sample and DNA from a Human Genomic DNA control from Roche 
(cat.no. 92084020). The reason why I have chosen this material is to save the 
material that I have from the patients, as it is difficult to get more material from 
these patients. However, in the last trials, I did use one patient sample. The reason 
for this is that the purification method then is the same as for all the patients I want 
to examine. The DNA is then amplified with the Taq DNA polymerase enzyme, PCR 
gold-buffer and MgCl2 from AmpliTaq Gold® with Geneamp® and a mixture of 
each deoxyribonucleoside triphosphate (dNTP)(Am. Pham. Biotec.). For the set-up 
of the first PCR reaction, I choose the combination from table 1. The PCR 
conditions were initial denaturation at 95 °C for 10 min., then 95 °C, 30 sec; 60 °C , 
30 sec.; 72 °C , 30 sec. for 35 cycles, final elongation at 72°C for 10 min. 
The PCR result from this set-up was very poor or very unspecific for the sequence 
after base13081 that might be because of the very high content of GC in the 
promoter P2 and exon 1B. 
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Table 1: The set-up conditions for Taq DNA polymerase PCR reaction. 
                                  µl pr. vial      
dH2O2                                 29.5 
PCR-gold buffer X 10     5 
dNTP 5 mM                    2 
MgCl2 25 mM     3 
Ampl.Tag.Gold 5 U/µl     0.5 
DNA-template 100ng/µl    4 
FW-primer 10µM                 3 
RV-primer 10µM                 3 
Total volume     50 
 
Another available enzyme for the amplification was the ThermalAce DNA 
polymerase (Invitrogen cat.no. E0200) that is an extremely thermostable enzyme 
from an archaebacterium that is designed for high yield PCR amplification of GC-
rich templates (> 65 % GC content) and has a five-fold more processitivity than 
Taq DNA polymerase. In addition, this enzyme works as good with templates with 
less contents of GC than 65%, which is the case for the first 1000 bases in the region 
I want to sequence. 
For the set-up of the Thermalace DNA polymerase PCR reaction, I chose the 
combination from table 2. 
Table 2: The set-up conditions for the ThermalAce DNA polymerase PCR reaction. 
                                  µl pr. vial     
dH2O2                                  36 
Thermalace buffer X 10     5 
dNTP 10 mM                    1 
Thermalace 2U/ µl   1 
DNA-template 400ng/µl    1 
FW-primer 10µM                  3 
RV-primer 10µM                 3 
Total volume  50 
 
The PCR conditions for ThermalAce DNA polymerase, was initial denaturation at 
98°C for 10 min.; then 98 °C, 30 sec; 60 °C, 30 sec.; 72 °C, 30 sec. for 35 cycles, final 
elongation at 72 °C for 10 min. During the gradient trials, the amount of each 
reagent has been reduced to half the volume to spare the reagent expenses. 
 
2.5 PCR verification and purification. 
 
To verify the PCR product and the right size of it, every PCR reaction was analyzed 
by a 2% agarose gel electrophoresis at 100mV in 1X TBE- buffer (see appendix p. 
32). Those PCR-products that fulfil to be the right size were purified through a GFX 
column. The principle is to bind the PCR product at a glass fibre matrix, and then 
wash off, the contaminants as proteins, salts, additional primers and primer-dimers 
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as they have a negative influence on the following sequence PCR, and then 
recover the purified PCR-product in a concentrated form by eluting with 50µl 
water. I have used GFX PCR DNA and Gel Band Purification Kit (Amersham 
Biosciences Pro.no. 27-9602-01). When the PCR product has been purified, it is 
ready to be used as a “template” in a sequence PCR reaction. 
 
2.6 Sequencing of the promoter areas and exons1A and 1B:  
 
Sequencing of the PCR fragments of the sequence of the area of promoter P1, 
exon 1A, promoter P2 and exon 1B in the CASR gene is done by labelling every 
single nucleotide both reverse and forward in every “template” PCR product. 
When I have used, 8 primers I have got 4 PCR fragments every one of them are 
labelled with a fluorescent dye for each of the 4 nucleotides A (adenine), C 
(cytosine), G (guanine), T (thymine). The principle is that the specific PCR product 
amplified by e.g. primer 304FW /1208RV is the template in a sequence PCR 
reaction and is amplified in 2 reactions respectively with a forward and a reverse 
primer together with the fluorescent dye containing the 4 different fluorescent 
dyes A, C, G, T (ABI Prism® BigDyeTM Terminator Cycle Sequencing Ready Reaction 
Kit). When the dye and the polymerase enzyme are mixed with the template and 
the respective primer, the PCR conditions for the sequencing was initial 
denaturation at 96°C for 1 min., then 96 °C, 10 sec; 50 °C, 5 sec.; 60 °C, 4 min. for 
25 cycles, in a thermocycler (Mastercycler gradient, Eppendorf). 
To get a “clean” fluorescent PCR product for sequencing the sequence PCR 
product is precipitated with alcohol and resuspended in water, to get rid of excess 
primer, primerdimers and salts. 
The “clean” fluorescent PCR product is then analysed on an ABI (Applied 
Biosystem 3100 Genetic Analyzer (ABI3100)), the principle in this analysis is 
electrophoresis of the fluorescence labelled nucleotides in the template PCR 
fragment of the specified sequence of the DNA sequence in the CASR gene, both 
forward and reverse. The result of this sequence analysis of all the primer-sets 
together with the template PCR should be a complete sequence of the promoter 
P1, exon 1A, promoter P2 and exon 1B in both sense and anti-sense strand of the 
CASR gene. The primer for sequence PCR is the same as in the first PCR reaction 
only in a smaller concentration, 2µl 1.6µM ~ 0.2 µM pr. reaction. For the set-up of 
the ABI Prism® BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit, PCR 
reaction, I chose the combination from table 3. 
Table 3: The set-up conditions for the ABI Prism® BigDyeTM Terminator Cycle Sequencing Ready 
Reaction Kit, PCR reaction. 
                                  µl pr. vial     
Big dye Terminator-mix (v. 3.1)    2 
Sequence-buffer X 5     3 
Primer 1,6 µM     2 
GFX purified PCR product   1 
dH2O2   12 
Total volume    20 
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Results: 
 
Until today, the collection of DNA have led to receiving of blood samples from 20 
patients; divided on eight patients with the diagnosis of primary hype-
rparathyroidism (PHPT), seven with familial hypocalciuremic hyperparathyroidism 
(FHH), four with auto-somal dominant hypoparathyroidism (ADH), two with severe 
neonatal hyper-parathyroidism (NSHPT) and two who has a dysfunctional calcium 
homeostasis. 
Following DNA purifications, the average concentrations were 767µg/µl and the 
purification ratios A260/ A280 between 1.5 – 1.9.     
 
My design and analysis of primers using the OLIGO 6 software for sequencing of 
the CASR gene for P1, P2, exons 1A and 1B  resulted in 4 reverse and 4 forward 
primers, see table 4. 
 
Primer Primer sequence Optimal annealing 
temp 
ORIGIN 
of CASR 
base no. 
  304 forward 5’GAGGTAGATGGTTATCGCCATT –‘3 55.9 °C 12 157 
  771 forward 5’CCCACCCAAGGAGTATGCTT –‘3 59.8 °C 12 624 
  966 forward 5’GCGCGCTGTGGAGTCGGGTAG –‘3 67.6 °C 12 819 
1509 forward 5’AGAAGGCAGCCCGCGAGTGG–‘3 62.5 °C 13 362 
  666 reverse 5’AAATAATATTCGTGCGGAGAT –‘3 52.0 °C 12 519 
1208 reverse 5’AACGTTCTCTGTGCCGAGGGT –‘3 61.8 °C 13 080 
1715 reverse 5’CTATGCCAAGGTCACGGTCTT –‘3 59.8 °C 13 590 
1975 reverse 5’CCCACGTTCACGCCCAATGCT –‘3 63.7 °C 13 848 
Table 4: The forward and reverse primers design for sequencing P1, P2, exons 1A and 1B in the CASR 
gene. 
 
The primers were meant to be in this way as primer-set for PCR amplification:  
1) 304 forward/ 1208 reverse ~ 904 bp, 2) 966 forward/ 1975 reverse ~1009bp and 
then all of the primers for sequencing because it is not possible to get more then 
300-500bp sequenced at a time on the ABI 3100 and to get both the strands of the 
DNA sequenced. 
The first set-up was with the Ampli taq gold enzyme and 1) primer set 304 forward/ 
1208 reverse ~ 904 bp and 2) 966 forward/ 1975 reverse ~1009bp, the only PCR 
product shown on these conditions was the one with primer 304 forward (fw) and 
1208 reverse (rv). See figure 8. 
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 M          H2O        1) at 60C°    H2O     2) at 60C°     H2O      2) at 65C°       M  
 
Figure 8: The set-up with primer-set: 1) 304fw/ 1208rv~904 bp and 2) 966 fw/ 1975 rv ~10
respective 60 °C and 65 °C. The red circle indicates the band of the correct size. For th
of the marker se appendix p.32. 
 
The next set-up was with Thermalace polymerase under the conditions a
described in the experimental procedure and a gradient of the tempera
the PCR with primer set 966fw/ 1975rv. As can be seen in figure 9 there a
products at 56. 3 °C to 72. 8 °C, but they are not specific.  
 
   M       53.5C°   54.5C° 56.3 C° 58.7 C°61.5C° 64.3C°   67.1C° 69.6C° 71.6 C° 72.8C°  H2
Figure 9: Set-up with Thermalace enzyme under the conditions as described in the met
and a gradient of the temperature for the PCR with primer set 966fw/ 1975rv. The red c
indicates a band of the correct size, the arrow a non-specific band. 
 
Then I tried to increase the temperature further without any better result.
attempt for optimization can then be either to change the magnesium 
concentration [Mg++] in the PCR reaction or the enzyme concentration 
reaction. In the next attempt, I increased the [Mg++] from 75mM to 87, 5 
reaction and at the same time I made a temperature gradient for the re
with the primer-set 966 fw/1975 rv~1009bp. The result can be seen in figu
best PCR product is seen at 73. 6 °C, but still it is not specific there is a no
band about 175 bp. 
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     M     64.0C°   64.6C°   65.6 C°  67.0 C°  68.7C°   70.4C°  72.1C°   73.6 C° 74.7 C°  75.5 C°    M 
Figure 10: Set-up with Thermalace enzyme under the conditions as described in the method part 
but with higher [Mg++] and a gradient of the temperature for the PCR with primer set 966fw/1975rv. 
The red circle indicates a band of the correct size, the arrow a non-specific band. 
 
In the next attempt, I tried another possible way of adjusting a PCR reaction, to 
increase the enzyme concentration. In the other reactions, I had used 2U 
Thermalace polymerase pr. reaction that I changed to 3U pr. reaction. In addition I 
made a PCR reaction with the other primers as well (966fw/1208rv ~ 242bp, - 
966fw/1715rv~749bp, -1509fw/1975rv~466bp, -771fw/1975rv ~1204bp, -966fw/1975rv 
~1009bp), at three different temperatures 61.2°C, 66.7°C, 72.7°C and a dena-
turation temperature at 95°C, instead of 98°C. The results are showed in figure 11.  
 
 
966fw/1208rv          966fw/1715rv   1509fw/1975 rv   771fw/1975rv    966fw/1975rv   
  ~ 242bp                    ~749bp                ~466bp             ~1204bp            ~ 1009bp 
M 61.2-  66.7- 72.7C°61.2- 66.7- 72.7C°61.2- 66.7-72.7C°61.2- 66.7-72.7C°61.2- 66.7- 72.7C°H2O M     
Figure 11: Set-up with Thermalace enzyme under the conditions as described in the methods part 
with 3U enzyme instead of 2U and a gradient of the temperature for each of the PCR’s with primer 
set 966 fw/ 1975rv- 966fw/1715rv -1509fw/1975 rv - 771fw/1975rv - 966fw/1975rv. The red circle 
indicates the band of the correct size, the arrow the non-specific bands. 
 
These results gave rise to some considerations. Now I have one specific PCR 
products 304fw/1208rv with amp. Taq. Gold polymerase and two specific PCR 
products 966fw / 1208rv and 1509fw/1975rv at 72.7 °C with Thermalace 
polymerase. Still it is not good enough; I did not see the product of base from 1208 
until 1975 with the very high content of GC. Any way now, the result is too much 
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PCR product and too many non-specific bands. I then tried a set-up with half the 
amount of DNA pr reaction. In addition, I increase the temperature gradient 
further to 72.6 °C, 73.4 °C, and 74.0 °C. These results are seen in figure 12. 
 
 
 
Figure 12: Set-up with Thermalace enzyme under the conditions as described in the methods part 
with 3U enzyme, 50ng DNA and a gradient of the temperature for each of the PCR with primer-set 
966 fw/1975rv- 966fw/1715rv -1509fw/1975rv - 771fw/1975rv - 966fw/1975rv. The red circles indicate 
the band of the correct size, the arrow the non-specific bands. 
 
This set-up gave the specific PCR product of three of the primer-sets 966fw/1208rv~ 
242bp, 1509fw/1975rv~466bp, and 966fw/1975rv ~ 1009bp at 74.0 °C. 
I still had too much PCR product that might be because I used the human 
genomic standard as template and I therefore will use this amount when I am 
testing the more natural material. I have afterwards tried hard to get the last two 
primer sets to succeed (966fw/1715rv, 771fw/1975rv) but without any luck.  
Within these experiences, I have accumulated the set-up to be as seen in table 5. 
for the Human Genomic DNA standard for primer-set 966fw/1208rv, 1509fw/1975rv, 
966fw/1975rv. The set-up for the primer-set 304fw/1208rv is as described in the 
experimental procedure. 
 
Table 5: The set-up conditions for amplifications of the sequence with high contents of GC. 
   µl pr. vial 
dH2O2                               17.0 
Thermalace buffer X 10     2.5 
dNTP 10 mM                    0.5 
Thermalace 2U/ µl   1.5 
DNA-template 200ng/µl                0.25 
FW-primer 10µM                  1.5 
RV-primer 10µM                 1.5 
Total volume  25 
966fw/1208rv          966fw/1715rv   1509fw/1975rv   771fw/1975rv    966fw/1975rv   
  ~ 242bp                    ~749bp                ~466bp             ~1204bp            ~ 1009bp 
M  72.6-  73.4- 74C°  72.6-  73.4- 74C°  72.6-73.4- 74C°  72.6-  73.4- 74C°   72.6- 73.4- 74C° H2O  M     
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The PCR conditions for Thermalace DNA polymerase, is initial denaturation at 95 °C 
for 10 min., then 95 °C, 30 sec; 74 °C, 30 sec.; 72 °C, 30 sec. for 35 cycles, final 
elongation at 72°C for 10 min. I then tested these conditions on a donor sample 
and a patient sample and as can be seen in figure 13 the donor sample has PCR 
products at 904bp, 242bp and the patient sample have additional at 1009bp and 
466bp. That means that there are products for the queried sequence. 
 
 
M Lane 2   3       H2O    5        6        H2O    8       9    H2O       11      12     H2O    14     15       H2O    M 
Figure 13: Set-up with Ampli Taq gold for 304fw/1208rv in lane 2 the donor sample and in lane 3 a 
patient sample. Set-up with Thermalace and primer-set 966fw/ 1208rv, 996fw/17151rv, 966fw/1975rv, 
1509fw/1975rv, in lane 5, 8, 11, 14 the donor sample and in lane 6, 9, 12, 15 a patient sample. The 
red circles indicate the band of the correct size. 
 
After this, the conclusion was to sequence the PCR products from lane 2, 3, 5, 6, 
12, 15, the band in lane 14 is an unspecific product with the wrong size. 
Unfortunately, one should not expect to get PCR-fragments longer than 300-500 
bp sequenced by the ABI 3100. That is why the PCR products longer then 300-500 
bp should be sequenced with several different primers to be sure to cover the 
whole sequence in both strands as seen in table 6. 
 
 “Template” PCR Sequenced with primer: 
                                            304fw, 771fw, 966fw  
   304 fw/1208 rv ~904bp                                             666rv, 1208rv 
                                            966fw  
   966 fw/ 1208 rv ~242bp                                             1208rv 
                                            966fw, 1509fw  
966 fw/ 1975 rv ~1009bp                                             1208rv, 1715rv, 1975rv 
                                            1509fw    
1509 fw/ 1975 rv~466bp                                             1975rv, 1715rv 
Table 6: The combination of primers for each template PCR product. 
 
The results of the sequencing of the donor and patient sample are the sequence 
of queried sequence for the bases12191till 12480, 12661 until 13080, 13361 until 
13848, when I consider the result from both the patient and the donor. It was not 
possible to get the queried sequence by one sample. That means that there is a 
gap of 181 bp in exon 1A and 281bp in the promoter 2 region; see the underlined 
sequence in appendix p. 33-34 figure 17.  
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I tested all the patients, but only for the PCR product amplified with primer-set 304 
fw/1208rv and 966fw/1975rv and sequenced those areas, which are possible with 
the same primer set.  
The test of all the patients included a PCR product in the right size and a successful 
analysis at the ABI 3100, the patients' number and their diagnosis can be seen in 
table 7 in the appendix at page 35.  
In figure 14 the PCR product of primer-set 304 forward/ 1208 reverse and the Ampl. 
Taq gold DNA polymerase, with the DNA from the diagnosed patients is seen, the 
band for the product is supposed to be 904 bp unfortunately there still is one 
unspecific band about 1000 bp although it is weak in relation to the wanted band.  
 
 
M    2    7   10  11  12  13   14 15   16   17 18   22  23  24   26  28  29  30  31  32  36  37   38  H2O M 
Figure 14: The PCR product of primer-set 304 forward/ 1208 reverse and the Ampl. Taq gold DNA 
polymerase, with the DNA from the diagnosed patients. The entire bands have the correct size of 
904bp, the arrow show one of the non-specific bands. 
 
In figure 15 the PCR product of primer-set 966 forward/ 1975 reverse and the 
Thermalace DNA polymerase, with the DNA from the diagnosed patients is seen, 
the band for the product is supposed to be 1009 bp unfortunately there still are 
many unspecific band although they are weak in relation to the wanted band.  
 
 
M   2   7   10   11   12  13  14  15  16  17 18  22  23   24  26 28  29  30  31  32  36  37  38 H2O  M   
Figure 15: The PCR product of primer-set 966fw/ 1975rv and the Thermalace DNA polymerase, with 
the DNA from the diagnosed patients. The red circle indicates a band of the correct size, the 
arrows the non-specific bands. 
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Because of the deadline of this project, I decided to try to sequence the PCR 
product from the DNA from the diagnosed patients without any further 
optimisation to see if there are any polymorphisms or mutations related to the 
diagnosis of the patients. For the sequencing, I use the same primer-sets as in the 
PCR amplification that means 304fw/1208rv, 966fw/1975rv. 
The results of the sequencing for the three different diagnoses; primary 
hyperparathyroidism (PHPT), familial hypocalciuremic hyperparathyroidism (FHH), 
autosomal dominant hypoparathyroidism (ADH) and severe neonatal 
hyperparathyroidism (NSHPT); are not as good as I wished. 
The results of the sequencing are rather disappointing because of the bad quality, 
after reading the 80 sequences by hand, I have tried to show the effect of the 
primer, seen in table 8. appendix page 35.  
The only primer giving some interesting results is 1975rv together with the 
966fw/1975rv "template" PCR. Here I have been able to sequence DNA from 7 
patients, where the results of nucleotide 13588-90 placed 111 nucleotides 
upstream of exon 1B' splice size, were found to be: GAG, GG/AG, GGG, as seen in 
figure 16. 
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a.    
 
Figure 16: 
The results of sequence 
analysis of the 
nucleotide 13588-90 
placed 111 nucleotides 
upstream of the splice 
size of exon 1B. 
Sequenced with the 
reverse primer 1975 
within the template PCR 
of primer-set 966fw / 
1975rv were there have 
been found one 
homozygote a) GAG, b) 
four heterozygous 
G(G/A)G, and c) two 
homozygous GGG from 
the seven diagnosed 
patients DNA that is 
analyzed. 
b.  
 
c. 
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Discussion: 
 
Because of the entire technical problem, the discussion has to be divided into two 
parts, a technical and a theoretical part. 
 
According to the technical result, I have used the Human Genomic DNA control 
for optimization to save the biologic material from the patients. That might have 
had some effect on the results for the PCR amplification. As can be seen in figure 
12-13 and 15 there is a large difference in the PCR products, which can be caused 
by the difference in the “quality” of the purified DNA. Considering the PCR product 
of 966fw/1975rv in figure 12 with the Human Genomic DNA control there is a large 
amount of PCR product compared to the amount from the amplification of the 
patient sample. The donor amplification with the primer set 966fw/ 1975rv was not 
successful. Compared with these set-ups the amount of PCR product from the 
diagnosed patients is in between but they are much more unspecific than both 
the Human Genomic DNA control and the donor and patient sample from the 
trials. The reason is probably the quality of the purified DNA. The Human Genomic 
DNA control is very “pure”, meaning that there is no contamination, such as heme 
from the blood where the samples are purified from, which could have some 
influence on the PCR amplification of this biological material.  Another difference 
between the two kinds of materials could be the secondary structure, which could 
be less in the control and thereby the annealing of the primer turn out to be better. 
In figure 13, it is obvious that there is a problem with the donor DNA to be amplified 
and that might be due to another purification method used for donor samples. 
That is also the reason why I did use one of the diagnosed patient's DNA in the last 
trials even though the material may be difficult to re-establish. 
The PCR result from the set-up with Ampified  taq gold polymerase is unspecific for 
some of the patients tested especially for patients no. 36, 37 and 38 that may owe 
to the reason that they have been purified only days before amplification, and 
thereby the quality of the DNA is so much better. To avoid this unspecific band one 
might use less DNA for the amplification and maybe increase the annealing-
temperature. 
 
The PCR result from all the set-ups with Thermalace enzyme was very unspecific for 
the sequence after base13081 (primer1208rv) and to base13848 (primer 1975rv) 
until the temperature was above 72.6 °C and the enzyme concentration was 
elevated 1.5 time. That might be because of the very high content of GC, which is 
70.5% in this area, where the promoter P2 and exon 1B is situated. The primer can 
have very difficult to anneal to the strand because the nucleotides G and C have 
a natural tendency to create “hair pins” by the annealing of G/C together in the 
same strand. This high content of GC might also be the reason why primer sets 
966fw/1715rv, 771fw/1975rv did not succeed because the sequence for the 
annealing of primer 1509fw and 1715rv is even higher, 78% of GC compared to 
primer-set 1509fw/ 1975rv, 966fw/1715rv and 966fw/ 1975rv. To solve the problems 
about amplification of primer-set 966fw/1715rv, 771fw/1975rv, it is necessary to 
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increase the temperature further, which is based on the fact that GC nucleotides 
have a higher melting temperature and thereby need a higher temperature to 
succeed in the annealing of primer.  
The PCR product of the patient DNA is quite unspecific for primer-set 966fw/ 1975rv 
related to that of the trials, the only difference here is the DNA quality. Because the 
unwanted band is weak related to the right one I think this problem could be 
solved by changing the amount of DNA to 25 ng pr. reaction instead of 50 ng as 
for the Ampli taq gold enzyme. 
After this, the conclusion was to sequence the PCR products from primer-set 304 
fw/1208rv and 966fw/1975rv with the combination of primer set in table 5 to be 
sure to cover the whole sequence in both strands. However, because of the 
deadline of this project I decided to try to sequence the PCR product from the 
DNA from the diagnosed patients, only with the same primer set as in the PCR 
amplification; that means 304fw/1208rv, 966fw/1975rv to see if there was any 
nucleotide change in those DNA sequences that I know I could get sequenced. I 
do know that these four primers were not able to cover the whole sequence. 
As shown in figure 19 and figure 20 (Appendix page 36-37) the sequencing with 
primer 304fw and 966fw have some trouble in elongation more then about 100 
bases respective 210 bases. That has to do with the repeat of respective 11 
adenosine nucleotides or 10 thymine nucleotides in the DNA sequence, even 
though the sequence in front of those multiple nucleotides is very satisfying. The 
sequencing with the forward primer 1208rv is often very unspecific with very high 
background of G and T nucleotides. This high background makes it difficult to 
determine the sequence. The sequencing has not went well either this has to be 
optimized at the template amplification or amplification for the sequencing or 
both. Indeed, there is another possibility for the bad result, which is the one that 
the ABI 3100 has an error, which I realized 2 weeks after this analysis. It shows up 
that the machine has been "burnt off” which means that there is not the right 
current between the two electrophoresis trays. So all the worries about how to 
increase the optimization might be unfounded, that might be that if I analyze the 
samples once again at the ABI 3100 when it is repaired I most likely will get as fine 
analysis sequenced as in the trial set-ups (Data not shown). 
As shown in the results part I have found some difference according to exon 1B 
reported on the sequence from respectively Canaff et al. 2002 and Chikatsu et al. 
2000, by sequencing with the primer 1975rv. Canaff has reported the sequence 
CATAGGGAGCGGGCTG and Chikatsu has the sequence 
CATAGAGAGCGGGCTG from base13584 to13600, the DNA variant is placed 111 
nucleotides upstream from splice size of exon 1 B. I succeed to sequence DNA 
from seven patients and found two patients with the GGG sequence, four patients 
with GG/AG and one patient with GAG.  
According to The National Center for Biotechnology Information (NCBI) the 
reference sequence is GGG (Figure 18 appendix page 35), the sequence that 
Chikatsu reported in 2000 GAG. Moreover, there have been reported a single 
nucleotide polymorphism (SNP) by some investigators who have screened the 
genomic library, testing a method for fast searches on databases containing 
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multiple gigabases of DNA (Ning et al., 2001). They find the sequence to be G 
(A/G) G. 
 
The patient I have found with the homozygous genotype GAG sequence happens 
to be diagnosed as PHPT, which is in accordance to the sequence reported by 
Chikatsu in 2000. Furthermore patient no. 7 also has PHPT and has the heterozygous 
G (G/A) G genotype, which could indicate the A-allele acts dominantly and may 
be a disease-causing mutation in PHPT patients. However, regarding the diagnosis 
of FHH there is a similar relationship, in which both the homozygous genotype, 
GGG, as well as the heterozygous genotype, G (G/A) G seem to be associated 
with the phenotype FHH. According to the ADH phenotype it seems that the 
genotype is G (G/A) G (see table 9 appendix page 36) The conclusion could be 
that the genotype GGG leads to FHH, the genotype GAG leads to PHPT and the 
heterozygous genotype G (G/A) G leads to all the phenotypes. 
Although these DNA variants may be related to a specific diagnosis, it is not 
possible to make any statements about polymorphisms or mutations before a 
background population has been sequenced and a wild type sequence has 
been found. 
Both the investigators have found that different mRNAs are expressed at different 
levels in different tissues, especially the parathyroid glands, thyroid C-cells and the 
kidney tissues where the CASR is important for the calcium homeostasis. The DNA 
variation found in this project is located 111 base pairs upstream from the splice 
site of exon 1B and this DNA variant would therefore not have any influence of the 
expression of different mRNA of the CASR or different expression levels in different 
tissues.  
However, it will be of highest interest to find some DNA variants in the promoter 
region, to see if there is a relationship between a mutation in the promoter; e.g. 
the TATA box for P1 or the GC-rich area for P2, or the Sp1 site where to C2H2 zinc 
finger binds, and the mRNA level related to one of the diagnoses. The other region 
of interest is the cis-acting elements; e.g. the transcription response element DVRE 
where to the D vitamin, a zinc finger structure, binds. This is interesting for two 
reasons; firstly, to see if a mutation gives rise to a stimulation or repression of the 
receptor and secondly because one of the treatments for PHPT is prescription of D-
vitamin and if DVRE has a mutation the treatment would not have the expected 
effect.  
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Perspectivation:  
 
This project has been very difficult for the technical part and it will require 
continued optimization with the primers I have to get a more specific PCR product 
when the DNA is amplified that could be done e.g.: 1) with higher temperature 2) 
higher magnesium concentration 3) changing the primer combination or 4) 
alternative solutions such as Betain or DMSO. If the PCR-amplification of the DNA 
were specific, the sequence quality would be better and thereby the analysis of 
the DNA sequence for the exon 1A and 1B and the respective promoter area. I am 
sure that if I could succeed in specific PCR product the primer set for sequencing 
in table 5 will cover the queried sequence. Another way could be to find another 
DNA-polymerase. I think will be difficult to find other primers. According to the 
Oligo 6 search I did it was very few of those primers I found that only have 1-2 "hits". 
A good idea for further optimization will be to use the same quality and quantity of 
DNA as one wish to analyse and to use sequence analyzer software to read the 
analyzed sequence to avoid the fail that inevitably will occur when the sequence 
is read manually. After being aware of the problems with the ABI 3500 I might not 
have to optimize any further.  
Even though I have had all these problems, those DNA variations I have found 
have given me even more interest in optimization the PCR if necessarily. And 
especially to se if there are some relation between the different diseased and the 
sequence of exon 1A and exon 1B or the respective promoter area including the 
TATA-box, CAAT-box, the binding site for the transcription factors Sp1, the binding 
sites for the transcription response elements VDRE and NF-кB. Well known that it will 
require analysis of 5-600 healthy persons to find a consensus sequence and the 
polymorphism in a background population.  
If there is found alterations in some of these areas it will be of most interest to 
analyse this alteration in a nuclear run-on analysis, to find the relative transcription 
rate for the CASR gene. Additionally to analyse the alterations in an “in vitro” 
functional cell study with a transfection system using luciferase as reporter. By 
these two analyses, it will be possible to determine whether the DNA alteration has 
consequences at the mRNA level or at the functional level of the CASR receptor. 
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Appendix: 
 
Purification of DNA:  
 
TE-buffer: 
 
10 X TE-buffer pH 7,3: 
 
Tris   0,1M, Titriplex  10M, demineralised water ad to 1000 ml. 
 
 
TBE-buffer: 
 
10 X TBE-buffer pH 8,0-8,3: 
 
Tris  0,89M, Boric acid  0,89M, EDTA-di-sodium  2mM, demineralised water ad to1000 
ml. 
 
 
Marker:  
Every agarose gel following electrophoretic separation is applied 1.6µg of this 
genruler where every single band refers to a specific basepair size. The DNA band 
can be visualised by ethidium bromide staining. This GeneRuler™ 100bp DNA 
Ladder Plus is distributing from Fermentas. 
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 NT_005612. Reports  Homo sapiens chro...[gi:37550867]  Links
LOCUS       NT_005612             128516 bp    DNA     linear   CON 23-AUG-2004 
DEFINITION  Homo sapiens chromosome 3 genomic contig. 
ACCESSION   NT_005612 REGION: 28384824..28513339 
VERSION     NT_005612.14  GI:37550867 
KEYWORDS  
SOURCE      Homo sapiens (human) 
 
ORIGIN 
11821                               aaaataaaat ctaaggtatt ttgataggca ccactactga gccacatcct 
11881 ccattactta cattgctggg tgtttcggcc tgagggagga cttcacattt attcctatta 
11941 accagatttt gccccttcac tggtgcttta gcatttgctc agctccttct cctaccctgt  
12001 atttgaggga aaggaagcca aatgggcaga acttggccat aatgaggatg tgtttgacat   
12061 gttccattga agaaaagaaa tggaaacttt gttgagtatc cattctatac agggcacttt 
12121 ccttgactat ttcatttaac actccaagga ccccctgagg tagatgttat cgccattttg 
12181 cagagaagaa atctgcattt ttatttgaag ttcttaaaca tggtaaacga cccaattttc 
12241 tgctttttgc ttaacagtat tttgcaaaca ttttatcatg ttacttcatg ttttcctatt 
12301 ttttttttgc tttataaata aatacatact ccctccttAT TCTAAAAAGA ATTTGAAGCA          
12361 CTTCTGTCTT GATGTTTATC ATTTTAATGG TTGTATAATG TCCCATTAAG TCACCCTAAT           
12421 TTATTCAACA AATTTCCTAC TGTTGACAGT TTGGCTCTGT TTGCTTTTTG TGGTTTTTAA 
304 FW 
NF-KB 
VDRE 
TATA - BOX 
CAAT - BOX
12481 AATTATTTTC TGTAACAAAT GATCCTGCTA AAAAAAAAAT CTCCGCACGA ATATTATTTT 
666 rv 
12541 GTTCTGGAAA TTTCCGCAAG GGTGGAATAC TGCATTAAAG GGGATAATAT TTTTGGTGTT 
12601 TCTTTATAGA GCCTAGCAAA TTGCCCACCC AAAGGAGTAT GCTTTATTTG AGAGTAAAAA 
12661 GCCAAAAACA AACAAACACA TACAAAAAAA CTGGTTTTCT ACAAAAGAAA TTAATTTTCC 
12721 ACTTATTCAT AAAATATTCT AGTGCTGTGA TGGGTGGCAG GCACCGTGCC AGGGGCTAGG 
12781 GACAAGGATA AGCAAGGCCA GGTCCGGGCC TCCAAGCAGC GCGCTGTGGA GTCGGGTAGA 
12841 GTAGACCAAG TGCAACAGGC ACCTGGCTGC AGCCAGGAAG GACCGCACGC CCTTTCGCGC 
12901 AGGAGAGTGG AAGGAGGGAG CTGTTTGCCA GCACCGAGGT CTTGCGGCAC AGGCAACGCT 
12961 TGACCTGAGT CTTGCAGAAT GAgtaagagt ttgggcacgc gatttgtatt tattttactg 
13021 tgaatctctg gccttatatc agaaaaaaaa aaattgtgcc accctcggca cagagaacgt 
13081 tggtggcgtc gtaagcgccc taagcttctt tccatcgcca aggagtaggg gtcagggaag 
13141 aggacagcgg gaacaggatt tgagagccgg gaacccctgg ctcggcacgg gagagggcag 
NF-KB 
771 fw 
NF-KB 
1280 rv 
966 fw 
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13201 gagaggacct aagcgcgggg ctcgccgtct gctggggacc cgagccggcc tgtggccctc 
13261 ggggaaccga agacgcgccc tcagcgaccc tgaagagtca gctaagctct ctgcgggcta 
13321 aggagacggt gaaggaaccg ggactaactg gggtaggggt tagaaggcag cccgcgagtg 
13381 ggctacgagg ggagctgggc tcggcagttg gggaccccga gggggcaagc gggcggggag 
13441 caGGAGAGGG GCGGAGCTCC GGGGCCGGGG CCGGGGCCGC AGCGGCCGCC CAGAGGGTCT 
13501 GCGGGGGCTG CTGTGGCCGG ACCCGAAGGC GGGCGCCGGG AGCGCAGCGA GCCAGACGCG 
13561 CCTCTCCAAG ACCGTGACCT TGGCATAGGG AGCGGGGCTG CGCGCAGTCC TGAGATCAGA 
13621 CCAGAGCTCA TCCTCGTGGA GACCCACGGC CGAGGGGCCG GAGCTGCCTC TGTGCGAGGG 
13681 AGCCCTGGCC GCGGCGCAGG taggaccggg gaacccaagg agggcgggag gaaagcgccc 
13741 ctggtggggg aggggccgtg gcggggtctg ggggccaagg gctccgggcc gaacgagggg 
13801 cacacgccgg agcagctcca gcctgggagc attgggcgtg aacgtggggg aaagtaggga  
 
Figure 17: The figure shows the entire sequence of interest for this project: 
 
• The BOLD AND BIG CAPITAL represent EXON 1A AND 1B from the sequence 
reported by Chikatsu et al., 2000 
• The BOLD AND ITALICS AND BIG CAPITAL represent EXONS 1A AND 1B from the 
sequence reported by Canaff et al., 2002. 
• Not bold and in small letters represent the promoter areas. The underlining is the 
non-sequenced area after the trials. 
• CAAT-BOX and the TATA-BOX are indicated by: 
• VDRE is indicated by: 
1509 fw 
VDRE
1715 rv 
Sp1 
Sp1 
1975 rv 
• Indicate the NF-кB: 
• g/A Indicate the Sp1 sites. 
• PRIMERS: the forward primers are in green: 304fw, 771fw, 966fw, 1509fw and the 
reverse primers is in blue: 666rv, 1208rv, 1715rv, 1975rv. 
• Transcription start site is indicated by: 
 34
ensemble: chromosome:NCBI35:3:123385823:123386467:1 
GCTCCGGGGCCGGGGCCGGGGCCGCAGCGGCCGCCCAGAGGGTCTGCGGGGGCTGCTGTG 
GCCGGACCCGAAGGCGGGCGCCGGGAGCGCAGCGAGCCAGACGCGCCTCTCCAAGACCGT 
GACCTTGGCATAGGGAGCGGGGCTGCGCGCAGTCCTGAGATCAGACCAGAGCTCATCCTC 
GTGGAGACCCACGGCCGAGGGGCCGGAGCTGCCTCTGTGCGAGGGAGCCCTGGCCGCGGC 
GCAGGTAGGACCGGGGAACCCAAGGAGGGCGGGAGGAAAGCGCCCCTGGTGGGGGAGGGG 
CCGTGGCGGGGTCTGGGGGCCAAGGGCTCCGGGCCGAACGAGGGGCACACGCCGGAGCAG 
CTCCAGCCTGGGAGCATTGGGCGTGAACGTGGGGGAAAGTAGGGACCAGATTACAGGATC 
AAGGCTTTCCCCGGCTCAGAACTGGATTGTTCAGTGCCCCTAGAAGGGGCAGCGGGTCGC 
CCACGCGAATGAACGGGAGCGCGCACCAAAACGCCTGCTGTTGGTAGTTTCTTGTGCCTC 
TGCCTTGTTTCTGCCTGTGATATAGTCAGAAAGGACTCGCTTGCCACGTGTTAACAAGGG 
GACAGGTAGCTTTTACAGAGTGTATGAATATGGAGGGGAGGGCCA 
 
Figure: 18. This figure shows that if you search a sequence for CASR in the human 
genomic sequence chromosome 3 in the ensemble database you will get the 
NCBI reference sequence as well as if you search direct at NCBI and that show the 
GGG in the position where I have found G (A/G) G.  
 
 
 
Patient 
diagnose 
FHH 
Inactivation 
ADH 
Activation 
PHPT SNHPT UN 
diagnosed 
Patient 
number 
10, 12, 17, 
30, 31, 37, 
38  
14, 15, 16, 
24 
7, 11, 13, 22, 
23, 26, 28, 
29 
2, 18 32, 36 
Table 7: The distribution of the diagnosis of the patient, who's DNA has been 
analyzed in this project. 
 
Table 8. The primer efficiency in the sequence reaction with the "template" PCR 
from the diagnosed patients.  
 
 
 
Primer 304fw 
 
Primer 1208rv 
 
Primer 966fw 
 
Primer 1975rv 
Un succeed 
sequence 
18, 22, 23, 24, 
26, 29, 30,31, 
32,  
7, 10, 13, 14, 
22, 32,  
10, 11, 16, 
17,18, 28, 30, 
32, 37, 38 
11, 12,13, 18, 22, 
23, 24, 26, 30, 32  
Low signal 13, 37, 38  29, 31,  10, 14, 28, 37, 38 
Un specific 
sequence 
10 11, 16, 17,18, 
23, 24, 26, 28, 
29, 37, 38 
 17,  
Perfect 
sequence 
7, 11, 12, 14, 
16, 17, 28,  
12, 30, 31 7, 12, 13, 14, 
15, 22, 23, 24, 
26,  
7, 15, 16, 17, 29, 
31,  
 35
 DNA variation   GGG GG/AG GAG 
Patients number 
and diagnosis 
17 FHH 
10 FHH 
15 ADH 
16 ADH 
7 PHPT 
31 FHH 
29 PHPT 
Table 9: The result of the sequence analyze of DNA from seven of the 23 
diagnosed patients, sequenced from base13584 to13600, placed 111 nucleotides 
upstream from splice size of exon 1B. 
 
 
 
 
Figure19: Sequencing with primer 304fw has some trouble in elongation more then 
about 100 bases. That has to due with the repeat of 10 thymine nucleotides in the 
DNA sequence.
 36
 
 
 
 
 
Figure 20: Sequencing with primer 966fw has some trouble in elongation more then 
210 bases. That has to due with the repeat of 11 adenosine nucleotides in the DNA 
sequence.  
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